Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in pseudomyxoma peritonei

Sørensen, Olaf; Flatmark, Kjersti; Reed, Wenche; Wiig, Johan N.; Dueland, Svein; Giercksky, Karl Erik; Larsen, Stein Gunnar

doi:10.1016/j.ejso.2012.06.552

Cited by 31 publications

(25 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of cCRS + HIPEC (with mitomycin C) allows to obtain many long-term survival rates in the majority of patients (10-year survival approx. 60%-70%) [7][8][9]. Sugarbaker et al analyzed 385 patients diagnosed with PMP, treated with cCRS (CCR0/CCR1) and HIPEC.…”

Section: Resultsmentioning

confidence: 97%

Treatment of peritoneal surface neoplasms with intraperitoneal chemotherapy in hyperthermia

Mielko

Ciaseł

Skórzewska

et al. 2015

Polish Journal of Public Health

View full text Add to dashboard Cite

Effective treatment of peritoneal surface neoplasms is possible through the simultaneous use of cytoreductive surgery with intraperitoneal chemotherapy in hyperthermia. It is successfully performed in patients with peritoneal pseudomyxoma, mesothelioma, as well as a limited and resectable peritoneal carcinomatosis in the course of colorectal cancer. It can also be used in patients with gastric or ovarian cancer but also metastatic colorectal cancer or metastases to the ovaries from gastric cancer. Aggressive surgical management of patients with primary or secondary neoplasms of the peritoneal surface was initiated by Sugarbaker's research group.

show abstract

Section: Resultsmentioning

confidence: 97%

Treatment of peritoneal surface neoplasms with intraperitoneal chemotherapy in hyperthermia

Mielko

Ciaseł

Skórzewska

et al. 2015

Polish Journal of Public Health

View full text Add to dashboard Cite

show abstract

“…To date, there have been no prospective studies comparing HIPEC versus EPIC as IPC technique following cytoreduction for appendiceal mucinous neoplasms. A recent retrospective study compared EPIC and HIPEC following optimal cytoreduction and showed no difference in overall or disease free survival .…”

Section: Resultsmentioning

confidence: 99%

Peritoneal debulking/intraperitoneal chemotherapy—non‐sarcoma

Kelly

Nash

2013

Journal of Surgical Oncology

View full text Add to dashboard Cite

The combination of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) is widely practiced for appendiceal, colorectal, gastric, and ovarian cancers with isolated peritoneal metastasis as well as for primary peritoneal cancer. The aim of this report is to explain the rationale and available techniques for CRS and IPC, and to highlight disease-specific considerations that should be taken into account when evaluating potential candidates for CRS and IPC.

show abstract

“…Modern treatment of PMP consists of CRS and HIPEC [12–14]. All macroscopically visible tumor masses within the peritoneal cavity are surgically removed if possible, and the patients receive subsequent perfusion of the abdominal cavity/peritoneum with heated chemotherapy, while still in general anesthesia [15].…”

Section: Discussionmentioning

confidence: 99%

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report

et al. 2018

View full text Add to dashboard Cite

BackgroundDiagnostic work-ups in transplanted immunosuppressed patients are a challenge as non-specific findings may be interpreted as transplant-related complications. If the disease in question is rare and slowly developing like pseudomyxoma peritonei (PMP), it is even more difficult. Cytoreductive surgery (CRS) and subsequent hyperthermic intraperitoneal chemotherapy (HIPEC) is the recommended treatment for PMP even with extensive peritoneal spread. CRS-HIPEC for PMP after liver transplantation (LTX) has not been described before.Case presentationA 48-year-old female patient with end-stage primary sclerosing cholangitis (PSC) underwent orthotopic LTX and subsequent pancreaticoduodenectomy after the finding of cholangiocarcinoma in situ in the native common bile duct. Ten years after the transplantation, she developed symptoms and signs suspected to represent graft-related complications. An extensive work-up revealed PMP. Upon reassessment, a cystic mass near the coecum could be seen on computed tomography scan 1 year after transplantation. The multidisiplinary team was hesitant to accept the patient for CRS-HIPEC because of extensive PMP and possible risk to the graft. However, she was eventually accepted and underwent the procedure. The Peritoneal Cancer Index (PCI) was 28 of 39, and surgical debulking was performed followed by HIPEC. The transplant control 2 months after surgery showed no harm to the graft.ConclusionsPrevious LTX should not exclude the possibility for CRS-HIPEC in PMP, even with extensive burden of disease.

show abstract

Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in pseudomyxoma peritonei

Cited by 31 publications

References 117 publications

Treatment of peritoneal surface neoplasms with intraperitoneal chemotherapy in hyperthermia

Treatment of peritoneal surface neoplasms with intraperitoneal chemotherapy in hyperthermia

Peritoneal debulking/intraperitoneal chemotherapy—non‐sarcoma

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report

Contact Info

Product

Resources

About